2560results about "Bacteria peptides" patented technology

Methods and systems are provided for generating and utilizing a genetically engineered bacterium comprising a modification in glnD, wherein said modification is selected from the group consisting of: deletion of the entire gene, deletion of substantially the entire gene, deletion of an ACT domain, deletion of more than 50% of an ACT domain, deactivation of an ACT domain, and deactivation of an UTase domain.

The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers.

Disclosed herein are engineered rhizobia having nif clusters that enable the fixation of nitrogen under free-living conditions, as well as ammonium and oxygen tolerant nitrogen fixation under free-living conditions. Also provided are methods for producing nitrogen for consumption by a cereal crop using these engineered rhizobia.

The invention provides lactobacillus crispatus, which is preserved in the general microbiological center of the China Committee for Culture Collection of Microorganisms on February 7, 2023, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No. 26503. The bacillus subtilis can play a relatively strong role in inhibiting pathogenic bacteria such as gardnerella vaginalis, escherichia coli and staphylococcus aureus at the same time, and also has a certain role in inhibiting candida albicans, two-way proteurella and Atortoria vaginalis. Therefore, the lactobacillus crispatus has the potential of maintaining the environment in the vagina to be faintly acid and improving the mucosal immunity and infection resistance of a host, and can be used for preventing and treating vaginal infection and inflammation, and maintaining, improving or recovering the steady state of the environment in the vagina.

The invention provides a production strain of an antibiotic-free plasmid, the production strain is a gene editing strain of a PIR strain and is named as PIR1-WN:: 0636 or PIR1-PR: 0636, the production strain contains a nucleotide sequence for coding toxin protein and the antibiotic-free plasmid, and the antibiotic-free plasmid contains a nucleotide sequence for coding antitoxin protein; and preferably, the replicon DNA element of the nonreactive plasmid is R6K-gamma. The toxin protein gene of the production strain disclosed by the invention can be stably passaged, has lethality after being induced and can be used for plasmid screening; according to the invention, the positive rate of transforming the nonreactive plasmid into the PIR1-WN:: 0636 strain is more than 80%, and stable production of the plasmid with a high superhelix ratio can be realized.

The invention discloses a modified bordetella pertussis strain and an application thereof. The modified Bordetella pertussis strain is characterized in that in the Bordetella pertussis strain BAA-589, the BP2992 protein is not expressed, or the inactive BP2992 protein is expressed, the pldA protein is not expressed, or the inactive pldA protein is expressed, and the mla F protein is not expressed, or the inactive mla F protein is expressed. When the Bordetella pertussis strain is treated by combining an ultrasonic method, compared with wild Bordetella pertussis BAA-589, the Bordetella pertussis strain has a remarkable high-foaming phenotype, the OMV secretion amount is remarkably increased, and a good technical foundation is laid for developing a Bordetella pertussis OMV vaccine.

The invention belongs to the field of animal vaccines, and particularly relates to a multi-epitope fusion protein aiming at multi-serotype laisseria parasuis antigen and application. The applicant carries out proteomics analysis on four clinical isolated strains of serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13 with high toxicity and good immunogenicity, and eight antigen proteins are screened out of the four clinical isolated strains of the serotypes 4, 5 and 13 of the parasuis leather serotype 4, 5 and 13. And further analyzing the screened eight antigen proteins to finally obtain the antigen multi-epitope fusion protein with immunogenicity capable of recognizing three serotypes. When the fusion protein is used as a vaccine, the protection rate of clinically separated piglets infected with a serum type 4 strain HB04, a serum type 5 strain SJZ05 and a serum type 13 strain GD20 reaches 100%.

The invention provides a recombinant halomonas capable of inducing protein self-degradation as well as a construction method and application of the recombinant halomonas. The recombinant halomonas does not express the SspB protein or the expressed SspB protein does not have functions or has reduced functions, and an SsrA tag is inserted into the C end of the to-be-degraded protein in the recombinant halomonas. The recombinant halomonas can degrade target protein in the middle and later stages of growth or the synthesis stage of products, and the method has the advantages of being easy to operate and small in influence on bacterial growth when used for achieving degradation of regulation and control protein.

The invention discloses a Graisseria parasuis three-component subunit vaccine and a preparation method thereof, and belongs to the technical field of biology. The vaccine comprises three kinds of antigen proteins of the Gleisseria parasuis in an immunizing dose and a pharmaceutically acceptable adjuvant, and the amino acid sequences of the three kinds of antigen proteins are respectively shown as SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3. The invention further discloses a preparation method of the vaccine. The three-component subunit vaccine provided by the invention has cross protection force on infection of type-4 and type-5 Graisseria parasuis, has an excellent immune protection effect, and is expected to play a better role in prevention and control of infectious diseases caused by the Graisseria parasuis.

The invention discloses a P450 mutant and application thereof in synthesis of calcifediol, and belongs to the technical field of bioengineering. According to the present invention, the P450 enzyme mutant enzyme is constructed, and the single plasmid three-enzyme co-expression system of the redox partner and the cofactor cycle enzyme is constructed, such that the sufficient electron transport chain is provided for the P450 enzyme, and the calcifediol can be efficiently synthesized under the mild condition by using the vitamin D3 as the substrate; the conversion rate of calcifediol can reach 63.1%, and the conversion rate of the reaction is greatly improved. By adopting the method disclosed by the invention, the catalytic efficiency of the catalyst is improved, and the reaction cost is reduced.

Disclosed herein are engineered rhizobia having nif clusters that enable the fixation of nitrogen under free-living conditions, as well as ammonium and oxygen tolerant nitrogen fixation under free-living conditions. Also provided are methods for producing nitrogen for consumption by a cereal crop using these engineered rhizobia.

The invention discloses an adjuvant and application thereof in vaccine preparation. The amino acid sequence of the adjuvant is shown as SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 23, 27, 31, 35 or 39. The immune protection effect of the nanoparticle vaccine can be improved by activating TLR2, and good vaccine adjuvant activity is shown in a common immunogen SD or new coronavirus RBD immunogen model. Furthermore, an assembly construction method of the self-adjuvant-nanoparticle vaccine is optimized, and the prepared self-adjuvant-nanoparticle vaccine has a remarkable effect of inducing the generation of an antibody in an animal body. The novel adjuvant provided by the invention can be widely applied to vaccine research and development, and meanwhile, the assembled nanoparticle self-adjuvant vaccine can also become a novel vaccine.

The invention relates to a recombinant pichia pastoris strain capable of producing astaxanthin at high yield as well as a construction method and application of the recombinant pichia pastoris strain. The recombinant pichia pastoris strain is obtained by expressing ATP (adenosine triphosphate) citrate lyase (ACL) and acetyl-CoA synthase (ACS) or phosphoketolase (PK) and phosphotransacetylase (PTA), choline kinase (CK), inositol polyphosphate kinase (IPK) and vitreoscilla hemoglobin (VHB) in host bacteria. Wherein the host bacterium is a pichia pastoris gene modified strain PP-LC2. The astaxanthin production performance of the recombinant strain is verified on the basis of comparison of precursor supply pathways, IUP pathway construction and improvement of the oxygen supply capacity of the engineering strain, and the astaxanthin production capacity of the pichia pastoris is further improved. The construction method of the recombinant pichia pastoris is simple, the synthesis of astaxanthin can be better promoted, the engineering strain can efficiently synthesize the astaxanthin by utilizing methanol through amplification fermentation of a 5L fermentation tank, and industrial production is facilitated.

The invention belongs to the technical field of gene engineering, and particularly relates to a mutant of polymyxin efflux transporter and application of the mutant. The mutant is a PmxD transporter mutant, the amino acid sequence of the PmxD transporter mutant is shown as SEQ ID NO: 1, and compared with wild type PmxD, the polymyxin transport capacity of the PmxD transporter mutant (T38W) is improved by 450.46%; and the total discharge amount of polymyxin is increased by 85.72%. Meanwhile, the mutant can significantly improve the growth ability of the strain on a plate containing 250 [mu] g / mL of polymyxin B, namely significantly improve the autoresistance of paenibacillus polymyxa to polymyxin.

Provided herein are isolated polynucleotides encoding a polypeptide comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. Also provided herein are isolated polynucleotides encoding alphaviral non-structural proteins nsp1, nsp2, nsp3, and nsp4 and polypeptides comprising an antigen protein fused to a signal sequence and a transmembrane domain, and optionally fused to a ferritin. The antigen may be influenza. Polynucleotides, such as RNAs, can be used as vaccines against influenza infection.

Provided herein are fusion polypeptides comprising an amino acid sequence of a bacteriocin, the amino acid sequence of the bacteriocin being a cleavage intein both on both the N-terminus and on both the C-terminus that cyclizes the bacteriocin. Also provided are nucleic acids and genetic vectors encoding the fusion polypeptides, as well as microbial cells genetically engineered with the nucleic acids or genetic vectors. Also provided are methods of making the cyclic bacteriocin, methods of screening using a library of nucleic acids or genetic vectors encoding the fusion polypeptides, and methods of controlling growth of organisms using the cyclic bacteriocin made by the methods provided herein.

The invention belongs to the field of gene engineering and biological treatment, and provides a hypoxia specific gene expression cassette, gram-negative bacteria containing the expression cassette and application of the gram-negative bacteria in preparation of tumor drugs. According to the invention, the forward hypoxia promoter and the reverse hyperxia promoter are reasonably designed, and appropriate survival essential genes are matched, so that the hypoxia specific gene expression cassette which is more efficient and safer is obtained. Gram-negative bacteria modified by the hypoxia specific gene expression cassette designed by the invention are low in overall mutation rate, and in a mouse in-vivo tumor model, more bacteria are distributed in tumors and the clearing speed in normal organs is higher.

A method for enhancing hydrogen uptake by cells of an acetogenic bacterium in a culture is provided. The method comprises incubating the cells in a liquid medium supplemented with an external gas mixture, wherein the external gas mixture comprises H2 and CO2; overexpressing an uptake hydrogenase and an associated electron transfer protein in the cells; increasing uptake of the H2 by the cells; and enhancing uptake of the CO2 by the cells. The culture may be a coculture with additional cells of a non-acetogenic bacterium, which produces natively H2 from catabolism of an organic molecule.

According to the invention, a structural domain reaction substrate sequence consisting of Exon1 (E1), P1 and Exon2 (E2) sequences of ribozyme is mutated, and E1, P1 and E2 sequences are mutated under the condition of maintaining the structural stability, so that the Azoarcus group I intron ribozyme still has enzyme activity and can maintain the capability of forming circular RNA (Ribose Nucleic Acid). The invention discloses a flexible vector construction method for preparing circular RNA (Ribonucleic Acid) without limitation of a substrate sequence, which comprises the following steps: determining a target to-be-cyclized site sequence NNUNNNN, and segmenting the target to-be-cyclized site sequence NNUNNNN into E1: NNU and E2: NNNN; with E1 and E2 sequences as references, designing IGS sequences to respectively form complementary pairing with E1 and E2; and 5'and 3 'homologous arms, IRES, CDS and other elements are respectively added. The method provided by the invention can be used for preparing the circular RNA for any target sequence, has no residual sequence, and has relatively high cyclization efficiency. The FlexCirc cyclization system designed on the basis of Azoarcus group I intron ribozyme can form the circular RNA, the cyclization substrate sequence has the characteristic of flexible design, and the cyclization efficiency can realize a relatively high cyclization proportion.

The invention relates to the technical field of antibacterial peptides, and discloses a novel Rhodospirillales antibacterial peptide and application thereof, and the amino acid sequence of the antibacterial peptide is as shown in SEQ ID NO: 1. The antibacterial peptide obtained by the invention has a relatively good antibacterial effect on staphylococcus aureus.

The invention relates to preparation, purification and application of a protein compound, and belongs to the technical field of biology. The present disclosure provides a protein delivery system comprising a protein complex and a signal peptide wherein the protein complex comprises a structural protein and a regulatory factor, the structural protein and the regulatory factor being from a Xenorhabdus khoisanae MCB strain. According to the present invention, the XkCIS protein complex structure gene and the lysR gene derived from the Xenorhabdus khoissanae MCB strain are expressed in the Escherichia coli, the expression and the assembly of the XkCIS protein complex in the bacteria are achieved, further, the effect protein is selectively fused with the signal peptide, and is loaded to the XkCIS protein complex under the guidance of the signal peptide, such that the XkCIS protein complex structure gene and the lysR gene are obtained, the specific delivery of the effect protein can be realized.

The present invention relates to a modified bacterium with anti-tumor activity, which comprises an essential gene expression cassette under the control of a strictly hypoxia inducible promoter and is deficient in at least one gene involved in or regulating the endogenous anti-oxidative stress response pathway or a functional expression product thereof. The present invention also relates to a pharmaceutical composition comprising the modified bacterium and anti-tumor use thereof.

Disclosed herein are methods of increasing nitrogen fixation in a non-leguminous plant. The methods can comprise exposing the plant to a plurality of bacteria. Each member of the plurality comprises one or more genetic variations introduced into one or more genes or non-coding polynucleotides of the bacteria's nitrogen fixation or assimilation genetic regulatory network, such that the bacteria are capable of fixing atmospheric nitrogen in the presence of exogenous nitrogen. The bacteria are not intergeneric microorganisms. Additionally, the bacteria, in planta, produce 1% or more of the fixed nitrogen in the plant.

The present invention addresses the problem of providing an improved RpBphP1 mutant and an improved RpPpsR2 mutant in such a manner that the binding and dissociation can be reliably controlled by light irradiation and shielding of near-infrared light. More specifically, the present invention is a proteome comprising two types of proteins that bind to each other under irradiation of near-infrared light, the proteome being a group of RpBphP1 mutants and wild-type RpPpsR2, a group of wild-type RpBphP1 mutants and RpPpsR2 mutants, or a group of RpBphP1 mutants and RpPpsR2 mutants, the binding of the proteome being greater than that of the wild-type RpBphP1 mutants and that of the wild-type RpPpsR2, and the binding of the proteome being less than that of the wild-type RpBphP1 mutants and that of the wild-type RpPpsR2. The binding in a dark place is weak and / or the binding under the irradiation of near-infrared light is strong.

The present application describes in part isolated and modified Enterococci toxin (Epx) polypeptides, immunogenic compositions comprising Exp polypeptides, nanopores formed by Epx polypeptides, apparatus comprising Epx nanopores, and methods of use thereof.

The present invention provides a Pediococcus pentosaceus ( Pediococcus pentosus ) strain ZPP083, which is deposited with the General Microbiology Center of the China National Center for Microbiological Culture Collection under the CGMCC No. 31944. The Pediococcus pentosaceus provided by the present invention has a strong antibacterial effect and produces a novel Class IIa bacteriocin with acid, heat, and protease resistance. The present invention also constructs a genetically engineered bacterium using this bacteriocin, increasing its expression.

The invention relates to a method for producing glycosylglycerol. The method comprises the following steps: S1, culturing trichocephalus microcoleus to a logarithmic phase; and S2, adding glycerol and glucose into the culture environment of the coleus microcoleus to induce the coleus microcoleus to accumulate the glycosylglycerol. According to the invention, by optimizing the culture of the coleus microcoleus BL0902, the production of the glycosylglycerol by using the strain is realized, and on the basis, the strain is subjected to metabolic engineering transformation, so that the yield of the glycosylglycerol is greatly improved by the obtained engineering strain.

The invention relates to plant lactobacillus and application thereof. Wherein the gene of the molecular marker for the plant lactobacillus has a nucleotide sequence selected from one of the following sequences: (1) a nucleotide sequence as shown in SEQ ID NO: 24; (2) a nucleotide sequence having at least 97%, 98%, 99% or higher homology with the nucleotide sequence as shown in SEQ ID NO: 24; and (3) a nucleotide sequence with one or more nucleotide sequences, such as 1, 2, 3, 4, 5 or more nucleotide substitutions, deletion or insertion, in the nucleotide sequence as shown in SEQ ID NO: 24. The plant lactobacillus provided by the invention is non-toxic, has good biological characteristics, has a good curative effect on prevention and / or treatment of vaginal infection and related diseases, and avoids the problems of increased drug resistance, high recurrence rate and the like caused by use of antibiotic and other antibacterial drugs during treatment of vaginal infection and related diseases.

The invention discloses a p-coumaric acid biosensor and application thereof, and the p-coumaric acid biosensor is characterized in that a coding gene of a CarR mutant, a Plpp1.6 promoter, a coding gene of a green fluorescent protein and a Pcar promoter mutant for controlling the expression of the green fluorescent protein are located on an expression vector pTrc99a; the biosensor provided by the invention realizes real-time sensitive monitoring of the concentration of coumaric acid by a recombinant escherichia coli strain containing the coumaric acid biosensor, can be combined with a high-throughput mutagenesis and screening system, and is beneficial to rapid and efficient screening of high-yield engineering strains of coumaric acid; and a technical guarantee is provided for production of p-coumaric acid and derivatives by efficient fermentation of microorganisms. The p-coumaric acid biosensor based on transcriptional regulatory factors is constructed, and a new strategy is provided for high-throughput screening.

A Bifidobacterium longum subsp. infantis YLGB-1496 postbiotic product, a bacteriocin, a preparation method, and a use, specifically relating to the technical field of probiotic postbiotics. The provided probiotic postbiotic product has the following biological functions: enhancing the intestinal barrier function, preventing and / or treating inflammatory bowel diseases, regulating gut flora, relieving intestinal flatulence and resisting oxidation, and has application prospects in preparing health-care foods or drugs for regulating gut flora and resisting oxidation.